• 1
    Pui CH,Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166178.
  • 2
    Koller CA,Kantarjian HM,Thomas D, et al. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 1997; 11: 20392044.
  • 3
    Aguayo A,Cortes J,Thomas D, et al. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer 1999; 86: 12031209.
  • 4
    Suki S,Kantarjian H,Gandhi V, et al. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer 1993; 72: 21552160.
  • 5
    Yamada K,Furusawa S,Saito K, et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: A pilot study. Leukemia 1995; 9: 1014.
  • 6
    Uckun FM,Gaynon PS,Sensel MG, et al. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: A Children's Cancer Group study. J Clin Oncol 1997; 15: 22142221.
  • 7
    Pui CH,Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998; 339: 605615.
  • 8
    Goldberg JM,Silverman LB,Levy DE, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 2003; 21: 36163622.
  • 9
    Einsiedel HG,von Stackelberg A,Hartmann R, et al. Long-term outcome in children with relapsed all by risk-stratified salvage therapy: Results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol 2005; 23: 79427950.
  • 10
    Saito K,Furusawa S,Yamada K, et al. Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia. Rinsho Ketsueki 1995; 36: 165174.
  • 11
    Saito K,Nakamura Y,Aoyagi M, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol 2000; 71: 238244.
  • 12
    Li JM,Shen Y,Wu DP, et al. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients. Int J Hematol 2005; 82: 4854.
  • 13
    Bai A,Kojima H,Hori M, et al. Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells. Exp Hematol 1999; 27: 259265.
  • 14
    Katagiri T,Miyazawa K,Nishimaki J, et al. Combination of granulocyte colony-stimulating factor and low-dose cytosine arabinoside further enhances myeloid differentiation in leukemia cells in vitro. Leuk Lymphoma 2000; 39: 173184.
  • 15
    Dutrillaux B,Lejeune J. A new technic of analysis of the human karyotype. C R Acad Sci Hebd Seances Acad Sci D 1971; 272: 26382640.
  • 16
    Pallisgaard N,Hokland P,Riishoj DC, et al. Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood 1998; 92: 574588.
  • 17
    Campana D,Coustan-Smith E,Janossy G. The immunologic detection of minimal residual disease in acute leukemia. Blood 1990; 76: 163171.
  • 18
    Ellison RR,Holland JF,Weil M, et al. Arabinosyl cytosine: A useful agent in the treatment of acute leukemia in adults. Blood 1968; 32: 507523.
  • 19
    World Health Organization. Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: WHO Offset Publication no., WHO; 1979.